{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:37:07Z","timestamp":1792679827482,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Malignant pleural mesothelioma (MPM) remains a rare but highly aggressive malignancy with limited treatment options and poor prognosis. For nearly twenty years, platinum\u2013pemetrexed chemotherapy has persisted as the unchanged standard treatment; although recent progress in immunotherapy has modestly disrupted this therapeutic plateau, survival outcomes remain disappointingly limited. This review aims to provide a comprehensive overview of the epigenetic landscape of MPM, focusing particularly on the oncogenic and therapeutic implications of enhancer of zeste homolog 2 (EZH2), and to discuss its potential as a target for novel therapeutic strategies and combination regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Epigenetic dysregulation has emerged as a central driver of mesothelioma pathogenesis. EZH2, the catalytic component of the polycomb repressive complex 2 (PRC2), mediates histone H3K27 trimethylation, silencing tumor suppressor genes and promoting malignant transformation. In addition to its canonical role, EZH2 has non-canonical oncogenic effects that modulate transcription, apoptosis, DNA repair, and immune evasion. High EZH2 expression correlates with BAP1 loss, which enhances chromatin remodeling defects and disease aggressiveness. Preclinical and early clinical data demonstrate that EZH2 inhibitors\u2014including tazemetostat, valemetostat, GSK126, EPZ011989, tulmimetostat, and novel PROTAC-based degraders such as MS1943\u2014can suppress tumor progression, modulate the tumor immune microenvironment, and restore therapeutic sensitivity. Furthermore, combination approaches integrating EZH2 inhibition with chemotherapy or immune checkpoint blockade show synergistic potential in overcoming resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>EZH2 represents a pivotal epigenetic regulator and a promising therapeutic target in MPM. Further understanding the dual canonical and non-canonical roles of EZH2 in tumor biology will be key to optimizing targeted and combinatorial treatment strategies. Future research should focus on translating EZH2 inhibition into clinical benefit, identifying predictive biomarkers of response, and exploring rational combinations with chemotherapy, targeted drugs, or immunotherapy to improve survival outcomes in mesothelioma patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11912-026-01754-x","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:48:14Z","timestamp":1782233294000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Role of EZH2 in Malignant Pleural Mesothelioma and Beyond: Current Practice and Future Perspectives"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-871X","authenticated-orcid":false,"given":"Mehmet","family":"Kucukoner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6334-4079","authenticated-orcid":false,"given":"Tarik","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abduljalil Mohammed","family":"Alsubaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4551-8439","authenticated-orcid":false,"given":"Ulas","family":"Alabalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha K","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2084-1029","authenticated-orcid":false,"given":"Mariaelena","family":"Pierobon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"Liotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"4","key":"1754_CR1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","volume":"149","author":"J Ferlay","year":"2021","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Intl J Cancer. 2021;149(4):778\u201389.","journal-title":"Intl J Cancer"},{"issue":"6","key":"1754_CR2","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1111\/crj.12778","volume":"12","author":"O Abdel-Rahman","year":"2018","unstructured":"Abdel-Rahman O. Global trends in mortality from malignant mesothelioma: analysis of WHO mortality database (1994\u20102013). Clin Respiratory J. 2018;12(6):2090\u2013100.","journal-title":"Clin Respiratory J"},{"issue":"14","key":"1754_CR3","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. JCO. 2003;21(14):2636\u201344.","journal-title":"JCO"},{"issue":"10272","key":"1754_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375\u201386.","journal-title":"Lancet"},{"issue":"10419","key":"1754_CR5","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","volume":"402","author":"Q Chu","year":"2023","unstructured":"Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and france: a phase 3, open-label, randomised controlled trial. Lancet. 2023;402(10419):2295\u2013306.","journal-title":"Lancet"},{"issue":"8","key":"1754_CR6","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1158\/1078-0432.CCR-20-4037","volume":"27","author":"K Oehl","year":"2021","unstructured":"Oehl K, Vrugt B, Wagner U, Kirschner MB, Meerang M, Weder W, et al. Alterations in BAP1 are associated with cisplatin resistance through Inhibition of apoptosis in malignant pleural mesothelioma. Clin Cancer Res. 2021;27(8):2277\u201391.","journal-title":"Clin Cancer Res"},{"key":"1754_CR7","first-page":"1","volume":"13","author":"A Davis","year":"2022","unstructured":"Davis A, Ke H, Kao S, Pavlakis N. An update on emerging therapeutic options for malignant pleural mesothelioma. Lung Cancer (Auckl). 2022;13:1\u201312.","journal-title":"Lung Cancer (Auckl)"},{"issue":"10","key":"1754_CR8","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022\u20135.","journal-title":"Nat Genet"},{"issue":"4","key":"1754_CR9","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","volume":"10","author":"M Nasu","year":"2015","unstructured":"Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H, et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol. 2015;10(4):565\u201376.","journal-title":"J Thorac Oncol"},{"issue":"28","key":"1754_CR10","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","volume":"36","author":"V Panou","year":"2018","unstructured":"Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol. 2018;36(28):2863\u201371.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1754_CR11","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8(12):1548\u201365.","journal-title":"Cancer Discov"},{"issue":"23","key":"1754_CR12","doi-asserted-by":"publisher","first-page":"9073","DOI":"10.1158\/0008-5472.CAN-09-1595","volume":"69","author":"Y Goto","year":"2009","unstructured":"Goto Y, Shinjo K, Kondo Y, Shen L, Toyota M, Suzuki H, et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res. 2009;69(23):9073\u201382.","journal-title":"Cancer Res"},{"issue":"3","key":"1754_CR13","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/ijc.29015","volume":"136","author":"Y Yoshikawa","year":"2015","unstructured":"Yoshikawa Y, Sato A, Tsujimura T, Otsuki T, Fukuoka K, Hasegawa S, et al. Biallelic germline and somatic mutations in malignant mesothelioma: multiple mutations in transcription regulators including mSWI\/SNF genes. Int J Cancer. 2015;136(3):560\u201371.","journal-title":"Int J Cancer"},{"key":"1754_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","volume":"6","author":"L Gan","year":"2018","unstructured":"Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018;6:10.","journal-title":"Biomark Res"},{"issue":"5595","key":"1754_CR15","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1076997","volume":"298","author":"R Cao","year":"2002","unstructured":"Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group Silencing. Science. 2002;298(5595):1039\u201343.","journal-title":"Science"},{"issue":"3","key":"1754_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41594-018-0036-6","volume":"25","author":"JW H\u00f8jfeldt","year":"2018","unstructured":"H\u00f8jfeldt JW, Laugesen A, Willumsen BM, Damhofer H, Hedehus L, Tvardovskiy A, et al. Accurate H3K27 methylation can be established de Novo by SUZ12-directed PRC2. Nat Struct Mol Biol. 2018;25(3):225\u201332.","journal-title":"Nat Struct Mol Biol"},{"issue":"7427","key":"1754_CR17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature11606","volume":"492","author":"MT McCabe","year":"2012","unstructured":"McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 Inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492(7427):108\u201312.","journal-title":"Nature"},{"issue":"3","key":"1754_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/cr.2011.22","volume":"21","author":"AJ Bannister","year":"2011","unstructured":"Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011;21(3):381\u201395.","journal-title":"Cell Res"},{"issue":"6113","key":"1754_CR19","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1227604","volume":"338","author":"K Xu","year":"2012","unstructured":"Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 2012;338(6113):1465\u20139.","journal-title":"Science"},{"key":"1754_CR20","doi-asserted-by":"publisher","first-page":"1233953","DOI":"10.3389\/fonc.2023.1233953","volume":"13","author":"SM Zimmerman","year":"2023","unstructured":"Zimmerman SM, Lin PN, Souroullas GP. Non-canonical functions of EZH2 in cancer. Front Oncol. 2023;13:1233953.","journal-title":"Front Oncol"},{"key":"1754_CR21","doi-asserted-by":"publisher","first-page":"175883592413060","DOI":"10.1177\/17588359241306026","volume":"17","author":"M Wozniak","year":"2025","unstructured":"Wozniak M, Czyz M. Exploring oncogenic roles and clinical significance of EZH2: focus on non-canonical activities. Ther Adv Med Oncol. 2025;17:17588359241306026.","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"1754_CR22","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/nm.3968","volume":"21","author":"KH Kim","year":"2015","unstructured":"Kim KH, Kim W, Howard TP, Vazquez F, Tsherniak A, Wu JN, et al. SWI\/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med. 2015;21(12):1491\u20136.","journal-title":"Nat Med"},{"issue":"8","key":"1754_CR23","doi-asserted-by":"publisher","first-page":"103644","DOI":"10.1016\/j.esmoop.2024.103644","volume":"9","author":"N Benzerdjeb","year":"2024","unstructured":"Benzerdjeb N, Dartigues P, Kepenekian V, Damiola F, Sequeiros R, Galateau-Salle F, et al. Update on gene fusions and the emerging clinicopathological landscape of peritoneal and pleural mesotheliomas and other neoplasms. ESMO Open. 2024;9(8):103644.","journal-title":"ESMO Open"},{"issue":"7","key":"1754_CR24","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668\u201372.","journal-title":"Nat Genet"},{"issue":"Suppl 1","key":"1754_CR25","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.21037\/tlcr.2019.11.15","volume":"9","author":"Y Yoshikawa","year":"2020","unstructured":"Yoshikawa Y, Emi M, Nakano T, Gaudino G. Mesothelioma developing in carriers of inherited genetic mutations. Transl Lung Cancer Res. 2020;9(Suppl 1):S67\u201376.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"1754_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/2767-9764.CRC-23-0276","volume":"4","author":"J Badhai","year":"2024","unstructured":"Badhai J, Landman N, Pandey GK, Song JY, Hulsman D, Krijgsman O, et al. Combined Inhibition of EZH2 and FGFR is synergistic in BAP1-deficient malignant mesothelioma. Cancer Res Commun. 2024;4(1):18\u201327.","journal-title":"Cancer Res Commun"},{"issue":"11","key":"1754_CR27","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm.3947","volume":"21","author":"LM LaFave","year":"2015","unstructured":"LaFave LM, B\u00e9guelin W, Koche R, Teater M, Spitzer B, Chramiec A, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015;21(11):1344\u20139.","journal-title":"Nat Med"},{"issue":"6","key":"1754_CR28","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","volume":"23","author":"MG Zauderer","year":"2022","unstructured":"Zauderer MG, Szlosarek PW, Le Moulec S, Popat S, Taylor P, Planchard D, et al. EZH2 inhibitor Tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2022;23(6):758\u201367.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1754_CR29","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","volume":"21","author":"M Gounder","year":"2020","unstructured":"Gounder M, Sch\u00f6ffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020;21(11):1423\u201332.","journal-title":"Lancet Oncol"},{"key":"1754_CR30","doi-asserted-by":"crossref","unstructured":"Chi SN, Joanna S, Yi. CoLab. [cited 2025 May 30]. Tazemetostat in patients with tumors with alterations in EZH2 or the SWI\/SNF complex: Results from NCI-COG Pediatric MATCH trial Arm C (APEC1621C). Available from: https:\/\/colab.ws\/articles\/10.1200%2Fjco.2022.40.16_suppl.10009","DOI":"10.1200\/JCO.2022.40.16_suppl.10009"},{"issue":"11","key":"1754_CR31","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/jnci\/djad085","volume":"115","author":"SN Chi","year":"2023","unstructured":"Chi SN, Yi JS, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey BD, et al. Tazemetostat for tumors harboring SMARCB1\/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J Natl Cancer Inst. 2023;115(11):1355\u201363.","journal-title":"J Natl Cancer Inst"},{"key":"1754_CR32","unstructured":"Joshua J, Meeks A, Shilatifard SD, Miller. A pilot study of tazemetostat and MK-3475 (pembrolizumab) in advanced urothelial carcinoma (ETCTN 10183). - ASCO [Internet]. [cited 2025 May 30]. Available from: https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT285529"},{"issue":"24","key":"1754_CR33","doi-asserted-by":"publisher","first-page":"7331","DOI":"10.1158\/1078-0432.CCR-18-4121","volume":"25","author":"TA Yap","year":"2019","unstructured":"Yap TA, Winter JN, Giulino-Roth L, Longley J, Lopez J, Michot JM, et al. Phase I study of the novel enhancer of Zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors. Clin Cancer Res. 2019;25(24):7331\u20139.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"1754_CR34","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1158\/0008-5472.CAN-24-0398","volume":"84","author":"PJ Keller","year":"2024","unstructured":"Keller PJ, Adams EJ, Wu R, C\u00f4t\u00e9 A, Arora S, Cantone N, et al. Comprehensive target engagement by the EZH2 inhibitor tulmimetostat allows for targeting of ARID1A mutant cancers. Cancer Res. 2024;84(15):2501\u201317.","journal-title":"Cancer Res"},{"key":"1754_CR35","unstructured":"Drescher C, Walter HS, Gastinne T et al. EZH2\/EZH1 inhibitor tulmimetostat (CPI-0209) in patients with advanced solid tumors or hematologic malignancies: Preliminary phase II results. - ASCO [Internet]. [cited 2025 May 30]. Available from: https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT403514"},{"issue":"16suppl","key":"1754_CR36","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1200\/JCO.2024.42.16_suppl.3097","volume":"42","author":"A Oaknin","year":"2024","unstructured":"Oaknin A, Banda K, Drescher C, Ribrag V, Kindler HL, Walter HS, et al. Phase II dose optimization with EZH2\/EZH1 inhibitor tulmimetostat in patients (pts) with advanced solid tumors or hematologic malignancies. JCO. 2024;42(16suppl):3097\u20133097.","journal-title":"JCO"},{"key":"1754_CR37","doi-asserted-by":"crossref","unstructured":"Taplin M-E, Hussain A, Shah S et al. Abstract CT094: Phase Ib results of ProSTAR: CPI-1205, EZH2 inhibitor, combined with enzalutamide (E) or abiraterone\/prednisone (A\/P) in patients with metastatic castration-resistant prostate cancer (mCRPC) | Request PDF. In: ResearchGate [Internet]. [cited 2025 May 30]. Available from: https:\/\/www.researchgate.net\/publication\/334221154","DOI":"10.1158\/1538-7445.AM2019-CT094"},{"key":"1754_CR38","doi-asserted-by":"publisher","first-page":"115122","DOI":"10.1016\/j.ejca.2024.115122","volume":"216","author":"V Ribrag","year":"2025","unstructured":"Ribrag V, Iglesias L, De Braud F, Ma B, Yokota T, Zander T, et al. A first-in-human phase 1\/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies. Eur J Cancer. 2025;216:115122.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1754_CR39","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41589-019-0421-4","volume":"16","author":"A Ma","year":"2020","unstructured":"Ma A, Stratikopoulos E, Park KS, Wei J, Martin TC, Yang X, et al. Discovery of a first-in-class EZH2 selective degrader. Nat Chem Biol. 2020;16(2):214\u201322.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"1754_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/1078-0432.CCR-11-0962","volume":"18","author":"CD Kemp","year":"2012","unstructured":"Kemp CD, Rao M, Xi S, Inchauste S, Mani H, Fetsch P, et al. Polycomb repressor Complex-2 is a novel target for mesothelioma therapy. Clin Cancer Res. 2012;18(1):77\u201390.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1754_CR41","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim KH, Roberts CWM. Targeting EZH2 in cancer. Nat Med. 2016;22(2):128\u201334.","journal-title":"Nat Med"},{"issue":"5","key":"1754_CR42","first-page":"513","volume":"80","author":"SM Hoy","year":"2020","unstructured":"Hoy SM, Tazemetostat. First Approval Drugs. 2020;80(5):513\u201321.","journal-title":"First Approval Drugs"},{"issue":"10","key":"1754_CR43","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood.2022016862","volume":"141","author":"K Izutsu","year":"2023","unstructured":"Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, et al. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma. Blood. 2023;141(10):1159\u201368.","journal-title":"Blood"},{"issue":"11","key":"1754_CR44","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1038\/s41416-024-02661-3","volume":"130","author":"N Landman","year":"2024","unstructured":"Landman N, Hulsman D, Badhai J, Kopparam J, Puppe J, Pandey GK, et al. Combination of EZH2 and ATM Inhibition in BAP1-deficient mesothelioma. Br J Cancer. 2024;130(11):1855\u201365.","journal-title":"Br J Cancer"},{"issue":"8","key":"1754_CR45","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1158\/0008-5472.CAN-18-2395","volume":"79","author":"S Huang","year":"2019","unstructured":"Huang S, Wang Z, Zhou J, Huang J, Zhou L, Luo J, et al. EZH2 inhibitor GSK126 suppresses antitumor immunity by driving production of Myeloid-Derived suppressor cells. Cancer Res. 2019;79(8):2009\u201320.","journal-title":"Cancer Res"},{"key":"1754_CR46","doi-asserted-by":"publisher","first-page":"678447","DOI":"10.3389\/fonc.2021.678447","volume":"11","author":"G Pinton","year":"2021","unstructured":"Pinton G, Wang Z, Balzano C, Missaglia S, Tavian D, Boldorini R, et al. CDKN2A determines mesothelioma cell fate to EZH2 Inhibition. Front Oncol. 2021;11:678447.","journal-title":"Front Oncol"},{"issue":"5","key":"1754_CR47","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1021\/acsmedchemlett.5b00037","volume":"6","author":"JE Campbell","year":"2015","unstructured":"Campbell JE, Kuntz KW, Knutson SK, Warholic NM, Keilhack H, Wigle TJ, et al. EPZ011989, A Potent, Orally-Available EZH2 inhibitor with robust in vivo activity. ACS Med Chem Lett. 2015;6(5):491\u20135.","journal-title":"ACS Med Chem Lett"},{"issue":"16suppl","key":"1754_CR48","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1200\/JCO.2023.41.16_suppl.3094","volume":"41","author":"C Drescher","year":"2023","unstructured":"Drescher C, Walter HS, Gastinne T, Lakhani NJ, Ribrag V, Rasco DW, et al. EZH2\/EZH1 inhibitor tulmimetostat (CPI-0209) in patients with advanced solid tumors or hematologic malignancies: preliminary phase II results. JCO. 2023;41(16suppl):3094\u20133094.","journal-title":"JCO"},{"issue":"10","key":"1754_CR49","doi-asserted-by":"publisher","first-page":"7016","DOI":"10.1021\/acs.jmedchem.2c00047","volume":"65","author":"J Xia","year":"2022","unstructured":"Xia J, Li J, Tian L, Ren X, Liu C, Liang C. Targeting enhancer of Zeste homolog 2 for the treatment of hematological malignancies and solid tumors: candidate Structure-Activity relationships insights and evolution prospects. J Med Chem. 2022;65(10):7016\u201343.","journal-title":"J Med Chem"},{"issue":"4","key":"1754_CR50","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nchembio.2306","volume":"13","author":"Y He","year":"2017","unstructured":"He Y, Selvaraju S, Curtin ML, Jakob CG, Zhu H, Comess KM, et al. The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex. Nat Chem Biol. 2017;13(4):389\u201395.","journal-title":"Nat Chem Biol"},{"issue":"6","key":"1754_CR51","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1021\/acs.jmedchem.6b01576","volume":"60","author":"Y Huang","year":"2017","unstructured":"Huang Y, Zhang J, Yu Z, Zhang H, Wang Y, Lingel A, et al. Discovery of First-in-Class, Potent, and orally bioavailable embryonic ectoderm development (EED) inhibitor with robust anticancer efficacy. J Med Chem. 2017;60(6):2215\u201326.","journal-title":"J Med Chem"},{"key":"1754_CR52","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3389\/fimmu.2018.00549","volume":"9","author":"G Chen","year":"2018","unstructured":"Chen G, Subedi K, Chakraborty S, Sharov A, Lu J, Kim J, et al. Ezh2 regulates Activation-Induced CD8\u2009+\u2009T cell cycle progression via repressing Cdkn2a and Cdkn1c expression. Front Immunol. 2018;9:549.","journal-title":"Front Immunol"},{"issue":"4","key":"1754_CR53","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.celrep.2017.07.007","volume":"20","author":"D Zingg","year":"2017","unstructured":"Zingg D, Arenas-Ramirez N, Sahin D, Rosalia RA, Antunes AT, Haeusel J, et al. The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy. Cell Rep. 2017;20(4):854\u201367.","journal-title":"Cell Rep"},{"issue":"5","key":"1754_CR54","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/cancers15051537","volume":"15","author":"MO Al Khatib","year":"2023","unstructured":"Al Khatib MO, Pinton G, Moro L, Porta C. Benefits and challenges of inhibiting EZH2 in malignant pleural mesothelioma. Cancers (Basel). 2023;15(5):1537.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1754_CR55","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"issue":"16","key":"1754_CR56","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.3390\/molecules26164740","volume":"26","author":"E Gabano","year":"2021","unstructured":"Gabano E, Pinton G, Balzano C, Boumya S, Osella D, Moro L, et al. Unsymmetric Cisplatin-Based Pt(IV) conjugates containing a PARP-1 inhibitor pharmacophore tested on malignant pleural mesothelioma cell lines. Molecules. 2021;26(16):4740.","journal-title":"Molecules"},{"issue":"6","key":"1754_CR57","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1158\/2159-8290.CD-23-0110","volume":"14","author":"Y Kazansky","year":"2024","unstructured":"Kazansky Y, Cameron D, Mueller HS, Demarest P, Zaffaroni N, Arrighetti N, et al. Overcoming clinical resistance to EZH2 Inhibition using rational epigenetic combination therapy. Cancer Discov. 2024;14(6):965\u201381.","journal-title":"Cancer Discov"},{"key":"1754_CR58","doi-asserted-by":"publisher","first-page":"216706","DOI":"10.1016\/j.canlet.2024.216706","volume":"586","author":"P Kaur","year":"2024","unstructured":"Kaur P, Shankar E, Gupta S. EZH2-mediated development of therapeutic resistance in cancer. Cancer Lett. 2024;586:216706.","journal-title":"Cancer Lett"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01754-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01754-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01754-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T18:02:44Z","timestamp":1782237764000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01754-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1754"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01754-x","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this paper was modified to update the Ethics statement.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"To the best of their knowledge, the authors confirm that the human subject studies referenced in this article were performed in accordance with the guidelines specified by the Declaration of Helsinki and the appropriate institutional review boards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.One exception is that MP receives royalties from Ignite Proteomics (formerly Theralink Technologies)","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}],"article-number":"65"}}